Rapport Therapeutics (RAPP) News Today

Rapport Therapeutics, Inc. (NASDAQ: RAPP) shares have climbed sharply on multiple positive catalysts this week, led by compelling mid‐stage clinical data for its lead epilepsy candidate, analyst price‐target upgrades and upbeat market reaction. Investors are also monitoring potential dilution from a proposed equity offering and a recent surge in bearish options activity.

• Positive Sentiment: Strong Phase 2a results for RAP-219 in focal-onset seizures showed a 77.8% reduction in clinical seizures (p=0.01) and 24% seizure freedom over eight weeks, sending the stock higher. Rapport rockets on positive trial data for RAP219
• Positive Sentiment: Shares more than doubled intraday after better-than-expected seizure drug data, reflecting growing investor enthusiasm for the epilepsy program. Rapport shares double on better-than-expected seizure drug data
• Positive Sentiment: HC Wainwright and other firms raised their RAPP price targets to $34.00 with “buy” ratings, implying over 20% upside from current levels. Price target raised
• Neutral Sentiment: Rapport filed for a $250 million underwritten public offering of common stock (with an option for an additional $37.5 million), subject to market conditions. Public offering announcement
• Negative Sentiment: Unusual activity saw 2,401 put options trade—up 3,484% from average—signaling a surge in bearish bets that could weigh on the stock. No link available